JP2017516752A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017516752A5 JP2017516752A5 JP2016559997A JP2016559997A JP2017516752A5 JP 2017516752 A5 JP2017516752 A5 JP 2017516752A5 JP 2016559997 A JP2016559997 A JP 2016559997A JP 2016559997 A JP2016559997 A JP 2016559997A JP 2017516752 A5 JP2017516752 A5 JP 2017516752A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- acid sequence
- seq
- amino acid
- sdvgeyr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 24
- 125000003275 alpha amino acid group Chemical group 0.000 claims 13
- 150000001413 amino acids Chemical class 0.000 claims 10
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 claims 5
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 claims 5
- 102000043131 MHC class II family Human genes 0.000 claims 5
- 108091054438 MHC class II family Proteins 0.000 claims 5
- 238000000034 method Methods 0.000 claims 4
- 150000007523 nucleic acids Chemical group 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 238000000338 in vitro Methods 0.000 claims 3
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 206010052779 Transplant rejections Diseases 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 238000012258 culturing Methods 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 239000001963 growth medium Substances 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 1
- 239000012472 biological sample Substances 0.000 claims 1
- 210000004443 dendritic cell Anatomy 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000006698 induction Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 239000013598 vector Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14163072 | 2014-04-01 | ||
| EP14163072.3 | 2014-04-01 | ||
| PCT/EP2015/057258 WO2015150492A2 (en) | 2014-04-01 | 2015-04-01 | An isolated donor mhc-derived peptide and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019219658A Division JP2020055844A (ja) | 2014-04-01 | 2019-12-04 | 単離されたドナーｍｈｃ由来ペプチド及びその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017516752A JP2017516752A (ja) | 2017-06-22 |
| JP2017516752A5 true JP2017516752A5 (enExample) | 2018-03-01 |
Family
ID=50390009
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016559997A Ceased JP2017516752A (ja) | 2014-04-01 | 2015-04-01 | 単離されたドナーｍｈｃ由来ペプチド及びその使用 |
| JP2019219658A Pending JP2020055844A (ja) | 2014-04-01 | 2019-12-04 | 単離されたドナーｍｈｃ由来ペプチド及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019219658A Pending JP2020055844A (ja) | 2014-04-01 | 2019-12-04 | 単離されたドナーｍｈｃ由来ペプチド及びその使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US10137181B2 (enExample) |
| EP (2) | EP3126374B1 (enExample) |
| JP (2) | JP2017516752A (enExample) |
| ES (1) | ES2702676T3 (enExample) |
| WO (1) | WO2015150492A2 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HK1255101A1 (zh) | 2015-07-03 | 2019-08-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | 用於得到调节性t细胞的方法及其用途 |
| WO2017042170A1 (en) * | 2015-09-07 | 2017-03-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | A new subpopulation of cd8+cd45rclow tregs and uses thereof |
| SG10202110335PA (en) * | 2016-04-06 | 2021-10-28 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against aml and other cancers |
| PL238939B1 (pl) * | 2016-11-02 | 2021-10-18 | Instytut Immunologii I Terapii Doświadczalnej Polskiej Akademii Nauk Im Ludwika Hirszfelda We Wrocławiu | Peptyd immunosupresyjny i jego zastosowania |
| JP7609775B2 (ja) | 2018-12-14 | 2025-01-07 | インセルム（インスティチュート ナショナル デ ラ サンテ エ デ ラ リシェルシェ メディカル） | 単離されたＭＨＣ由来ヒトペプチドおよびＣＤ８＋ＣＤ４５ＲＣｌｏｗＴｒｅｇの抑制機能を刺激し、かつ活性化するためのその使用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5593698A (en) * | 1990-10-31 | 1997-01-14 | Autoimmune, Inc. | Suppression of proliferative response and induction of tolerance with polymorphic class II MHC allopeptides |
| EP0563485A1 (en) | 1992-03-30 | 1993-10-06 | Schering-Plough | In vitro generation of human dendritic cells and uses thereof |
| AU687733B2 (en) | 1992-04-01 | 1998-03-05 | Rockefeller University, The | Method for in vitro proliferation of dendritic cell precursors and their use to produce immunogens |
| US5635363A (en) | 1995-02-28 | 1997-06-03 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for the detection, quantitation and purification of antigen-specific T cells |
| FR2798128B1 (fr) | 1999-09-06 | 2001-11-16 | Inst Nat Sante Rech Med | Moyens de detection et de purification de populations lymphocytaires t cd8+ specifiques de peptides presentes dans le contexte hla |
| JP2007538000A (ja) * | 2004-01-08 | 2007-12-27 | リージエンツ・オブ・ザ・ユニバーシテイ・オブ・カリフオルニア | 制御性ｔ細胞は自己免疫を抑制する |
| SI1642905T1 (sl) * | 2004-10-02 | 2009-04-30 | Immatics Biotechnologies Gmbh | Imunogeni T-pomagalni epitop iz humanega tumornega antigena in imunoterapevtski postopki, ki uporabljajo navedeni epitop |
| EP2032695B1 (en) * | 2006-05-31 | 2018-08-15 | The Regents of The University of California | Cd127 expression inversely correlates with foxp3 and suppressive function of cd4+ tregs |
| US20090004213A1 (en) * | 2007-03-26 | 2009-01-01 | Immatics Biotechnologies Gmbh | Combination therapy using active immunotherapy |
| RU2015142245A (ru) * | 2013-03-13 | 2017-04-18 | Кур Фармасьютикалз Дивелопмент Компани | Иммуномодифицирующие частицы для лечения воспаления |
-
2015
- 2015-04-01 EP EP15715708.2A patent/EP3126374B1/en not_active Not-in-force
- 2015-04-01 US US15/300,331 patent/US10137181B2/en not_active Expired - Fee Related
- 2015-04-01 EP EP18204496.6A patent/EP3495377A1/en not_active Withdrawn
- 2015-04-01 JP JP2016559997A patent/JP2017516752A/ja not_active Ceased
- 2015-04-01 ES ES15715708T patent/ES2702676T3/es active Active
- 2015-04-01 WO PCT/EP2015/057258 patent/WO2015150492A2/en not_active Ceased
-
2019
- 2019-12-04 JP JP2019219658A patent/JP2020055844A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250134978A1 (en) | Rna cancer vaccines | |
| Shklovskaya et al. | MHC class I deficiency in solid tumors and therapeutic strategies to overcome it | |
| AR127116A2 (es) | Péptidos y combinación de péptidos novedosos para su uso en inmunoterapia contra diversos tumores | |
| JP2021192630A (ja) | 生体分子の免疫細胞への送達 | |
| RS62612B1 (sr) | Postupci za dobijanje jednolančane rnk | |
| JP2017516752A5 (enExample) | ||
| JP2017524337A5 (enExample) | ||
| JP2014534202A5 (enExample) | ||
| JP2013521789A5 (enExample) | ||
| EP4368705A3 (en) | Method for generating t-cells compatible for allogenic transplantation | |
| Monti et al. | Human plasmacytoid dendritic cells and cutaneous melanoma | |
| Salvato et al. | Immunotherapeutic strategies for the treatment of glioblastoma: current challenges and future perspectives | |
| JP2015510393A5 (enExample) | ||
| Terbuch et al. | Next generation cancer vaccines—make it personal! | |
| JP2017536826A5 (enExample) | ||
| JP2019512020A5 (enExample) | ||
| Simmons et al. | T-cell-based cellular immunotherapy of multiple myeloma: current developments | |
| JP2017515795A5 (enExample) | ||
| WO2015150492A3 (en) | An isolated donor mhc-derived peptide and uses thereof | |
| CN107001418A (zh) | 源于hsp70的肽、使用其的用于治疗或预防癌症的医药组合物、免疫诱导剂、及抗原呈递细胞的制造方法 | |
| JPWO2010126081A1 (ja) | 不溶性蛋白質及び／又はペプチドの可溶化方法 | |
| Hsieh et al. | A GMCSF and IL7 fusion cytokine leads to functional thymic‐dependent T‐cell regeneration in age‐associated immune deficiency | |
| Zheng et al. | Biological effects of bone marrow mesenchymal stem cells on hepatitis B virus in vitro | |
| UA124331C2 (uk) | Пептид, здатний зв'язуватися з молекулою головного комплексу гістосумісності (mhc) людини i класу | |
| KR20240161969A (ko) | 종양 항원, 종양 항원 kras, tpx2 또는 aurka을 포함하는 화합물 및 그 용도 |